Humana (NYSE:HUM) Stock Rating Lowered by Jefferies Financial Group

Humana (NYSE:HUM) was downgraded by Jefferies Financial Group from a “buy” rating to a “hold” rating in a note issued to investors on Monday, MarketBeat.com reports. They presently have a $253.00 target price on the insurance provider’s stock, down from their previous target price of $519.00. Jefferies Financial Group’s price objective points to a potential upside of 4.03% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley began coverage on Humana in a research note on Monday, June 24th. They set an “equal weight” rating and a $374.00 price objective on the stock. UBS Group dropped their target price on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, October 4th. Bank of America lowered Humana from a “neutral” rating to an “underperform” rating and decreased their price target for the company from $376.00 to $247.00 in a report on Wednesday, October 2nd. Oppenheimer dropped their price objective on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 price objective on shares of Humana in a research report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, eighteen have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Humana presently has an average rating of “Hold” and a consensus price target of $324.86.

Humana Trading Up 2.9 %

HUM stock opened at $243.20 on Monday. The firm has a fifty day moving average price of $334.58 and a 200 day moving average price of $342.37. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $530.54. The firm has a market cap of $29.31 billion, a PE ratio of 15.14, a price-to-earnings-growth ratio of 2.44 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same period last year, the company posted $8.94 EPS. The business’s revenue was up 10.4% on a year-over-year basis. Sell-side analysts anticipate that Humana will post 16.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Daymark Wealth Partners LLC lifted its stake in Humana by 27.2% in the third quarter. Daymark Wealth Partners LLC now owns 1,865 shares of the insurance provider’s stock worth $591,000 after acquiring an additional 399 shares during the period. Future Financial Wealth Managment LLC bought a new stake in shares of Humana in the 3rd quarter valued at about $158,000. Tealwood Asset Management Inc. lifted its position in shares of Humana by 1.8% in the 3rd quarter. Tealwood Asset Management Inc. now owns 4,276 shares of the insurance provider’s stock worth $1,354,000 after purchasing an additional 76 shares during the period. Dynamic Advisor Solutions LLC boosted its stake in shares of Humana by 4.7% during the third quarter. Dynamic Advisor Solutions LLC now owns 3,832 shares of the insurance provider’s stock valued at $1,214,000 after purchasing an additional 171 shares in the last quarter. Finally, Axiom Advisory LLC boosted its stake in shares of Humana by 1.6% during the third quarter. Axiom Advisory LLC now owns 3,648 shares of the insurance provider’s stock valued at $1,155,000 after purchasing an additional 57 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.